article thumbnail

Normunity de-stealths, launches Series A immune normalisers

pharmaphorum

has exited stealth with a $65 million Series A to create a new class of medicines that target novel I-O mechanisms, which free the body’s normal immunity against cancer. Called “immune normalisers”, these targets are drawn from an ongoing and interactive academic-biotech research alliance within the Yale School of Medicine.

article thumbnail

STAT+: Medicare would have saved $3.7 billion on Part B drugs if inflationary rebates were around in a recent three-year period

STAT

More specifically, 70 of the 93 top-selling drugs covered by the Medicare Part B program – which are typically pricier medicines that are administered by physicians or in hospitals – between 2018 and 2020 would have been subject to inflationary rebates each year, according to the analysis published in JAMA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Bringing the promise of immunotherapy to a broader population

pharmaphorum

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. That’s what makes them such a tricky detective mystery!

article thumbnail

Eli Lilly and Gilead’s combination cuts COVID-19 recovery time

pharmaphorum

Lilly is continuing talks with the FDA around the potential for an Emergency Use Authorisation for Olumiant, which has been approved since 2018 in the US to treat rheumatoid arthritis. The drug works by inhibiting janus kinase (JAK1 and JAK2), which has the effect of reducing the activity of the immune system.

article thumbnail

Roche rings Bicycle bell again, grabbing another cancer target

pharmaphorum

In 2016 it started a $1 billion alliance with AstraZeneca to find drug candidates that could be used to treat respiratory diseases, and extended that in 2018 to include cardiovascular and metabolic disorders. Roche isn’t the only big pharma partner Bicycle has attracted for its bicyclic peptide technology.

article thumbnail

Sanofi and Translate take first mRNA flu vaccine into clinic

pharmaphorum

The US-based trial will enrol up to 280 participants aged 18 to 49 and will evaluate the safety of the mRNA vaccine candidate given at several dose levels, as well as its ability to stimulate an immune response against H3N2. billion, including $450 million of milestones from the original 2018 agreement.

Vaccines 114
article thumbnail

Merck and Moderna partner to develop and sell cancer vaccine

Pharmaceutical Technology

They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018. The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.

Vaccines 115